{"database":"JPOST Repository","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Raw":["https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F3.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F7.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F5.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F5.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F3.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F1.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F7.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F9.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F2.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F11.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F4.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F2.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F8.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F6.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET2_Global_F8.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F4.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F10.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F12.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F1.raw","https://storage.jpostdb.org/JPST004140/files/210829_WAT_SET1_Global_F6.raw"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Sang-Ku Yoo"],"species":["Mus Musculus (mouse)"],"full_dataset_link":["https://repository.jpostdb.org/entry/JPST004140"],"submitter_affiliation":["Jeju univesity"],"sample_protocol":[""],"repository":["jPOST"],"data_protocol":[""],"pubmed_abstract":["Current anti-obesity therapies that suppress appetite often cause undesirable reductions in lean mass by indirectly depleting systemic energy store. In this study, we developed a novel anti-obesity drug, Vutiglabridin (VUTI), designed to selectively reduce fat mass while preserving lean mass. We evaluated its efficacy in high-fat diet-induced obese (DIO) mice and investigated its underlying mechanism in in vitro adipocyte models. VUTI dose-dependently and selectively decreased fat mass, resulting in normalization of body weight within 3 weeks while preserving lean mass. Pharmacokinetic and mechanistic analyses revealed that VUTI targets white adipose tissue (WAT), where it enhances lipid degradation through AMPK-mediated lipophagy in both mouse and human adipocytes. The lipid degradation-enhancing effect of VUTI was shown to be dependent on paraoxonase 2 (PON2). Multi-omics analyses, including proteomic and transcriptomic profiling of epididymal WAT in DIO-mice, further confirmed this mechanism. Collectively, these findings demonstrate that VUTI represents a promising therapeutic strategy for obesity by inducing fat-selective reduction via AMPK-mediated lipophagy."],"pubmed_title":["Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes."],"pubmed_authors":["Lee Hyeong Min HM, Lee Jae Ho JH, Kim Sang Hyo SH, Marakkalage Kamindu Gayashan KG, Hur Jihyeon J, Park Hyung Soon HS, Kim Kwang Pyo KP, Shin Gu-Choul GC, Yoo Sang-Ku SK"],"additional_accession":[]},"is_claimable":false,"name":"Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes","description":"Current anti-obesity therapies that suppress appetite often cause undesirable reductions in lean mass by indirectly depleting systemic energy store. In this study, we developed a novel anti-obesity drug, Vutiglabridin (VUTI), designed to selectively reduce fat mass while preserving lean mass. We evaluated its efficacy in high-fat diet–induced obese (DIO) mice and investigated its underlying mechanism in in vitro adipocyte models. VUTI dose-dependently and selectively decreased fat mass, resulting in normalization of body weight within 3 weeks while preserving lean mass. Pharmacokinetic and mechanistic analyses revealed that VUTI targets white adipose tissue (WAT), where it enhances lipid degradation through AMPK-mediated lipophagy in both mouse and human adipocytes. The lipid degradation-enhancing effect of VUTI was shown to be dependent on paraoxonase 2 (PON2). Multi-omics analyses, including proteomic and transcriptomic profiling of epididymal WAT in DIO-mice, further confirmed this mechanism. Collectively, these findings demonstrate that VUTI represents a promising therapeutic strategy for obesity by inducing fat-selective reduction via AMPK-mediated lipophagy.","dates":{"publication":"Thu Apr 30 00:00:00 BST 2026"},"accession":"PXD069901","cross_references":{"TAXONOMY":["10090"],"pubmed":["41237461"]}}